Why the study?
Renal dysfunction is a recognized risk factor for poor cardiovascular outcomes in older patients, but the implications of CKD in young patients presenting with AMI are not well studied.
Does the presence of chronic kidney disease increase the risk of all-cause mortality in young adults with acute myocardial infarction?
Does the presence of chronic kidney disease increase the risk of all-cause mortality in young adults with acute myocardial infarction?
In young adults presenting with acute myocardial infarction, underlying chronic kidney disease is associated with a 3.6-fold increased risk of long-term mortality and lower utilization of guideline-directed medical therapies.
CKD prevalence in young AMI patients merits attention in risk assessment; leaves open whether targeted interventions alter outcomes.
OBJECTIVE: The goal of this study was to evaluate the prevalence of chronic kidney disease (CKD) in young patients with acute myocardial infarction (AMI) and to report their characteristics and clinical outcomes. BACKGROUND: Underlying renal dysfunction is a risk factor for poor cardiovascular outcomes in older patients. The implication of CKD in young patients with AMI is not well studied. METHODS: This is a retrospective population-based cohort study of patients aged 18-50 who presented with AMI between 2006 and 2016. Medical records were reviewed to confirm diagnosis and to identify treatment and long-term outcomes. Cox regression models were used to evaluate the association of CKD with mortality. RESULTS: Among 1753 young patients with type 1 AMI (median age 45 years, 85.3% male), CKD was present in 112 (6.8%) patients. A higher proportion of CKD patients had concomitant hypertension, hyperlipidemia, diabetes, and obesity. Use of statin and P2Y12 inhibitors post-AMI was lower in CKD patients. Over a median follow-up of 7.2 years, CKD was associated with higher all-cause mortality [hazard ratio (HR), 9.3; 95% CI, 6.3-13.8]. This association persisted after adjusting for demographics, comorbidities, and treatment (adjusted HR, 3.6; 95% CI, 2.2-6.0). CONCLUSION: Presence of CKD was associated with 3.6-fold higher mortality over a median follow-up of 7.2 years. A lower proportion of CKD patients were treated with statin therapy and P2Y12 inhibitors. These findings highlight the need for intensive risk factor modification and optimal use of guideline-directed medical therapies in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Gyurjian et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: